Akcea Therapeutics Inc (NASDAQ:AKCA) hit a new 52-week low on Friday . The company traded as low as $20.80 and last traded at $20.80, with a volume of 1463 shares changing hands. The stock had previously closed at $21.73.
A number of brokerages have weighed in on AKCA. Zacks Investment Research raised Akcea Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 4th. ValuEngine lowered Akcea Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $39.40.
The company has a debt-to-equity ratio of 0.04, a current ratio of 6.61 and a quick ratio of 3.31. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -7.63 and a beta of 1.39.
Akcea Therapeutics (NASDAQ:AKCA) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.24 by ($0.90). The company had revenue of $163.82 million during the quarter, compared to the consensus estimate of $171.40 million. Akcea Therapeutics had a negative return on equity of 54.63% and a negative net margin of 79.88%. The company’s revenue was up 857.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.44) earnings per share. Equities analysts predict that Akcea Therapeutics Inc will post -0.63 EPS for the current year.
In other news, COO Jeff Marc Goldberg sold 50,000 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $31.71, for a total value of $1,585,500.00. Following the completion of the transaction, the chief operating officer now directly owns 32,880 shares of the company’s stock, valued at approximately $1,042,624.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Paula Soteropoulos sold 31,787 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $32.11, for a total value of $1,020,680.57. Following the completion of the transaction, the chief executive officer now directly owns 30,000 shares of the company’s stock, valued at $963,300. The disclosure for this sale can be found here. Over the last three months, insiders sold 130,173 shares of company stock valued at $4,148,407. Corporate insiders own 3.64% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc increased its position in Akcea Therapeutics by 17.8% during the 3rd quarter. Legal & General Group Plc now owns 2,237 shares of the company’s stock valued at $79,000 after buying an additional 338 shares in the last quarter. Quantamental Technologies LLC purchased a new stake in Akcea Therapeutics during the 1st quarter valued at about $74,000. BNP Paribas Arbitrage SA grew its stake in Akcea Therapeutics by 842.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 3,165 shares of the company’s stock valued at $90,000 after purchasing an additional 2,829 shares during the last quarter. Marshall Wace North America L.P. purchased a new stake in Akcea Therapeutics during the 1st quarter valued at about $106,000. Finally, SG Americas Securities LLC purchased a new stake in Akcea Therapeutics during the 4th quarter valued at about $116,000. 25.26% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Akcea Therapeutics (AKCA) Hits New 12-Month Low at $20.80” was posted by Modern Readers and is owned by of Modern Readers. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.modernreaders.com/news/2019/05/17/akcea-therapeutics-akca-hits-new-12-month-low-at-20-80.html.
Akcea Therapeutics Company Profile (NASDAQ:AKCA)
Akcea Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy.
Recommended Story: What is the cash asset ratio?
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.